On the 9th of February, Orbimed Advisors added 475 thousand Terns Pharmaceuticals, Inc. (TERN) shares for $8.1 million at an average price of $17.00 per share. Shares of Terns Pharmaceuticals, Inc. are down -0.96% since the transaction.
Orbimed Advisors's holding in Terns Pharmaceuticals, Inc. increased to about 2.3 million shares with the purchase.